India’s diagnostic laboratory regulations are facing renewed scrutiny over what healthcare advocates describe as a gap between the standards imposed on laboratories serving government health beneficiaries and the minimum requirements applicable to diagnostic facilities more broadly.

The debate follows a report by ETHealthworld highlighting differences between the Central Government Health Scheme (CGHS) empanelment requirements and the implementation of the Clinical Establishments Amendment Rules, 2018, which prescribe minimum operational standards for medical diagnostic laboratories.

Under CGHS guidelines, diagnostic laboratories seeking empanelment must have National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, along with full-time pathologists and quality managers. The requirements also specify minimum patient volumes of 100 patients per day in Tier-I cities and 50 per day in Tier-II and Tier-III cities and northeastern states.

The guidelines prescribe requirements for specialist personnel, equipment and laboratory infrastructure. These include fully automated five-part haematology analysers, fully automated biochemistry analysers, hormone analysers and microbiology processing units, depending on the services offered.

By comparison, the Clinical Establishments framework classifies laboratories into three categories—basic composite, medium and advanced—and sets standards according to their scope of services. These cover infrastructure, equipment, staffing, record maintenance and operational practices. The framework also specifies qualifications for technical heads, specialists and authorised signatories, with provisions varying according to laboratory category and investigation type.

The difference has prompted questions about whether stronger safeguards should be extended to laboratories serving patients outside government health schemes. Malini Aisola of the All India Drug Action Network and consultant pathologist Dr Anan Jaiswal have criticised the disparity, arguing that ordinary patients also require consistent quality assurance and professional oversight.

The issue is significant given the role diagnostic testing plays in clinical decision-making. Inaccurate results, inadequate quality control or inappropriate report authorisation can affect diagnosis and treatment. Accreditation, qualified personnel, suitable equipment and reliable reporting procedures are therefore important components of laboratory quality.

However, the criticism concerns the consistency of regulation and implementation, rather than an announcement of new national rules. The Clinical Establishments standards already prescribe minimum requirements, while implementation and enforcement remain central challenges. The rules do not impose a universal requirement for every laboratory to employ a full-time pathologist or maintain NABL accreditation, unlike the conditions described for CGHS empanelment.

The debate raises a broader policy question: how can India ensure that quality and patient-safety safeguards are consistently applied across diagnostic services, regardless of whether patients are covered by a government scheme or pay out of pocket? Clear implementation responsibilities, proportionate oversight and effective quality monitoring will be important to addressing these concerns.